Biotech
-
alvarez via Getty Images
BioMarin drops drug programs in pipeline cull
The cuts of four pipeline prospects come as BioMarin resets its priorities following the slow launch of its hemophilia gene therapy Roctavian.
By Kristin Jensen • April 25, 2024 -
Permission granted by Regeneron
Gene editingRegeneron expands in gene editing with Mammoth deal
“With each passing year, we're more committed to becoming a serious player in the genetic medicine space,” a Regeneron executive said.
By Gwendolyn Wu • April 25, 2024 -
Explore the Trendline➔
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
TrendlineCOVID-19 vaccines
The urgency of the pandemic’s first two years is giving way to questions of how to sustain public health responses and prepare for what could come next. In the U.S., health officials are urging booster shots and preparing for private sector distribution of vaccines.
By BioPharma Dive staff -
Permission granted by Biogen
Biogen: Don’t expect any big acquisitions this year
While the company is eager to diversify, CEO Chris Viehbacher said any near-term dealmaking would likely focus on collaborations and early-stage assets.
By Jacob Bell • April 24, 2024 -
Maddie Meyer via Getty Images
Moderna turns to AI to change how its employees work
An expanded partnership with OpenAI is helping Moderna embed custom-built AI chatbots in a wide range of research and business processes.
By Ned Pagliarulo • April 24, 2024 -
Courtesy of Eisai
New Alzheimer's drugsBiogen to invest more in launch of Alzheimer’s drug Leqembi
Growing demand has convinced Biogen that it's worth expanding the sales force around Leqembi by 30%.
By Jacob Bell • April 24, 2024 -
William Walker/BioPharma Dive
Sponsored by Allucent[Podcast] Partner for Progress: Strategies for Biotech Success
In this three-part podcast series, hear from seasoned experts from Allucent as they discuss a range of topics, including how small and mid-sized companies can take a more strategic approach to pharmacovigilance, a regulatory & development roadmap for ADCs and RDCs, and pre-MAA/NDA inspection readiness.
April 24, 2024 -
Courtesy of CureVac AG
CureVac to cut costs in restructuring
The mRNA vaccine maker, which has lost most of its value since early 2021, is undergoing an “organizational redesign” that will eliminate 150 positions.
By Kristin Jensen • April 24, 2024 -
Permission granted by Endeavor Biosciences
Emerging biotechEndeavor pulls in $132M to back cancer, lung disease drugs
Led by the founder of a biotech Celgene acquired for $7 billion, the startup is developing two prospects that originated in the labs of other drugmakers.
By Gwendolyn Wu • Updated April 24, 2024 -
koto_feja via Getty Images
Neurocrine scores surprise win with depression drug
Shares of the biotech rose about 5% after a medicine licensed from Takeda hit the main and key secondary goals of a mid-stage study focused on major depressive disorder.
By Jacob Bell • April 23, 2024 -
Courtesy of Ipsen
Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases
The deal, which could be worth up to $1.8 billion, is the latest research collaboration involving small molecule drugs that modify RNA.
By Delilah Alvarado • April 22, 2024 -
Courtesy of Takeda Pharmaceuticals
Pharmas form joint venture to jumpstart Japanese drug research
A new initiative backed by Takeda, Astellas and Sumitomo Mitsui Banking aims to combat a decade-long decline in drug R&D productivity in Japan.
By Ben Fidler • April 22, 2024 -
Permission granted by Cerevel Therapeutics
Cerevel, in ‘major surprise,’ finds success in late-stage Parkinson’s study
Analysts had low expectations for Cerevel’s drug tavapadon, which was something of an afterthought in AbbVie’s proposed buyout of the biotech.
By Ned Pagliarulo • April 18, 2024 -
Douglas Cliff via Getty Images
Emerging biotechMetsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo
It’s “early innings” in the obesity drug race, said Metsera CEO Clive Meanwell, whose company acquired a portfolio of medicines it aims to test in combination.
By Ben Fidler • April 18, 2024 -
noparrit via Getty Images
Sage’s cognition drug fails in Parkinson’s study
Following negative results, the company doesn’t plan to further test SAGE-718 in Parkinson’s. Other studies in Huntington’s and Alzheimer’s remain ongoing.
By Jacob Bell • April 17, 2024 -
Permission granted by Canaan
Canaan hires Pfizer executive, reels in $100M for biotech investing
The firm has brought in as venture partner Uwe Schoenbeck, who most recently was the top scientist for Pfizer’s emerging science and innovation unit.
By Gwendolyn Wu • April 17, 2024 -
Dr_Microbe via Getty Images
Cullinan changes name, pivots to autoimmune disease
The biotech says a dual-pronged antibody it’s developing could become an “off-the-shelf” alternative to cell therapies in development for lupus and other inflammatory conditions.
By Kristin Jensen • April 16, 2024 -
Courtesy of Alexandria Real Estate Equities
Q&A // Emerging biotechBiotech landlord Alexandria on research clusters and the sector’s recovery
Joel Marcus, the longtime head of Alexandria Real Estate Equities, sees few near-term challengers to the established biotech hubs of Boston, San Diego and San Francisco.
By Gwendolyn Wu • April 16, 2024 -
Permission granted by Neumora Therapeutics
Neumora’s schizophrenia drug hit with clinical hold
Shares of the biotech dipped by double digits following disclosure the FDA had paused an early-stage study of Neumora’s muscarinic-targeting drug.
By Jacob Bell • April 15, 2024 -
Regeneron commits $500M to new venture capital fund
While corporate venture arms are commonplace among pharmaceutical companies, the new fund announced Monday is Regeneron’s first.
By Delilah Alvarado • April 15, 2024 -
Spencer Platt via Getty Images
Biotech IPOs bounced back in first quarter, but backlog remains
Proceeds from biotech IPOs during the first three months of 2024 matched levels seen in the first quarters of 2019 and 2020, BioPharma Dive data show.
By Gwendolyn Wu • April 12, 2024 -
luismmolina via Getty Images
Emerging biotechCentury buys a startup, raises funding in cell therapy expansion
The biotech is acquiring Clade Therapeutics and its stem cell technology at a discount price, while adding $60 million via a private placement led by Bain Capital.
By Delilah Alvarado • April 11, 2024 -
PeopleImages via Getty Images
J&J, Rallybio partner on drug development for rare fetal condition
The biotech is working on a preventive therapy for the immune disorder, known as FNAIT for short, while J&J is studying its drug nipocalimab as a treatment.
By Delilah Alvarado • April 10, 2024 -
whitehoune via Getty Images
Emerging biotechPureTech launches Seaport, hoping to create Karuna 2.0
The startup is taking aim at anxiety with $100 million from high-profile biotech backers like ARCH, Sofinnova and Third Rock.
By Jacob Bell • April 9, 2024 -
Adene Sanchez via Getty Images
Private biotech funding rises as venture firms deploy cash
Twenty-six drugmakers closed fundraising rounds worth more than $100 million in the first quarter, according to HSBC data shared with BioPharma Dive.
By Gwendolyn Wu • April 8, 2024 -
Permission granted by Bristol Myers Squibb
Deep DivePsychiatry drugs finally have pharma’s attention. Can they keep it?
Recent biotech company acquisitions have put emerging schizophrenia treatments in focus. But many development hurdles still stand in the way of new medicines for the brain.
By Jacob Bell • April 8, 2024
